Hansa Biopharma AB logo

HNSA - Hansa Biopharma AB Share Price

SEK161.1 3.3  2.1%

Last Trade - 2:54pm

Mid Cap
Market Cap £596.8m
Enterprise Value £480.2m
Revenue £518k
Position in Universe 441st / 1830
Unlock HNSA Revenue
Relative Strength (%)
1m +2.52%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -45.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
6.68 2.58 3.44 3.36 3.36 6.10 84.5 176.5 -1.8%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, HansaBiopharma AB revenues increased 81% to SEK6.1M. Net lossincreased 17% to SEK420.9M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsSelling/General/Admin. Expense increase of 21% to SEK203M(expense), Research and development expenses increase of18% to SEK227.2M (expense), G/L on Invest. HFS.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for HNSA
Graphical History


HNSA Revenue Unlock HNSA Revenue

Net Income

HNSA Net Income Unlock HNSA Revenue

Normalised EPS

HNSA Normalised EPS Unlock HNSA Revenue

PE Ratio Range

HNSA PE Ratio Range Unlock HNSA Revenue

Dividend Yield Range

HNSA Dividend Yield Range Unlock HNSA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
HNSA EPS Forecasts Unlock HNSA Revenue
Profile Summary

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since October 17, 2007
No. of Shareholders: 17,000
No. of Employees: 87
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 44,473,452
Free Float (0.0%)
Eligible for
HNSA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for HNSA
Upcoming Events for HNSA
Wednesday 23rd June, 2021 Estimate
Hansa Biopharma AB Annual Shareholders Meeting
Frequently Asked Questions for Hansa Biopharma AB
What is the Hansa Biopharma AB share price?

As of 2:54pm, shares in Hansa Biopharma AB are trading at SEK161.1, giving the company a market capitalisation of £596.8m. This share price information is delayed by 15 minutes.

How has the Hansa Biopharma AB share price performed this year?

Shares in Hansa Biopharma AB are currently trading at SEK161.1 and the price has moved by 60.25% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Hansa Biopharma AB price has moved by 24.69% over the past year.

What are the analyst and broker recommendations for Hansa Biopharma AB?

Of the analysts with advisory recommendations for Hansa Biopharma AB, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Hansa Biopharma AB is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Hansa Biopharma AB next release its financial results?

Hansa Biopharma AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Hansa Biopharma AB dividend yield?

Hansa Biopharma AB does not currently pay a dividend.

Does Hansa Biopharma AB pay a dividend?

Hansa Biopharma AB does not currently pay a dividend.

When does Hansa Biopharma AB next pay dividends?

Hansa Biopharma AB does not currently pay a dividend.

How do I buy Hansa Biopharma AB shares?

To buy shares in Hansa Biopharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Hansa Biopharma AB?

Shares in Hansa Biopharma AB are currently trading at SEK161.1, giving the company a market capitalisation of £596.8m.

Where are Hansa Biopharma AB shares listed? Where are Hansa Biopharma AB shares listed?

Here are the trading details for Hansa Biopharma AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: HNSA
What kind of share is Hansa Biopharma AB?

Based on an overall assessment of its quality, value and momentum, Hansa Biopharma AB is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Hansa Biopharma AB share price forecast 2021?

Shares in Hansa Biopharma AB are currently priced at SEK161.1. At that level they are trading at 97.5% discount to the analyst consensus target price of 0.00.

Analysts covering Hansa Biopharma AB currently have a consensus Earnings Per Share (EPS) forecast of -11.14 for the next financial year.

How can I tell whether the Hansa Biopharma AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hansa Biopharma AB. Over the past six months, the relative strength of its shares against the market has been -44.63%. At the current price of SEK161.1, shares in Hansa Biopharma AB are trading at -27.27% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Hansa Biopharma AB PE Ratio?

We were not able to find PE ratio data for Hansa Biopharma AB.

Who are the key directors of Hansa Biopharma AB?

Hansa Biopharma AB's management team is headed by:

Emanuel Bjorne - VBD
Christian Kjellman - COO
Birgit Norinder - IND
Henk Doude van Troostwijk - SVP
Ulf Wiinberg - CHM
Soeren Tulstrup - PRE
Anders Pedersen - IND
Andreas Eggert - IND
Max Sakajja - VPR
Donato Spota - CFO
Eva Nilsagard - IND
Mats Blom - IND
Anne Safstrom Lanner - VPR
Who are the major shareholders of Hansa Biopharma AB?

Here are the top five shareholders of Hansa Biopharma AB based on the size of their shareholding:

Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 10.4% (4.63m shares)
Handelsbanken Asset Management Investment Advisor/Hedge Fund
Percentage owned: 5.25% (2.33m shares)
Consonance Capital Management LP Hedge Fund
Percentage owned: 4.97% (2.21m shares)
Nexttobe AB Venture Capital
Percentage owned: 4.85% (2.16m shares)
Invesco Advisers, Inc. Investment Advisor
Percentage owned: 4.5% (2.00m shares)
Similar to HNSA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.